| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_518aa05039ede807465f2c62fdaba973
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ef8c99132bac3a585de77f9dca6109d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ce0bd5f29fb4dd75c6d86844c35ede5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ffa84703555981ea4edd1af0083019d0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2009-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aba396806b59d634c912c0d1abd6f5f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2301521ef1bb6a1960c5faad0024503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f43fddd22eb70868c8fa24d92fba5efd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3db60543066f90025755d578bf0f39b |
| publicationDate |
2010-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010075329-A1 |
| titleOfInvention |
Methods for predicting production of activating signals by cross-linked binding proteins |
| abstract |
The present invention provides human binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL21R), and uses therefore. The invention further provides methods to predict whether the binding proteins of the invention may take on agonistic activities in vivo and produce a cytokine storm. In addition, the invention provides methods for determining whether an anti-IL21R binding protein is a neutralizing anti-IL21R binding protein, based on the identification of several IL21-responsive genes. The binding proteins can act as, e.g., antagonists of IL21R activity, thereby modulating immune responses in general, and those mediated by IL21R in particular. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10739353-B2 |
| priorityDate |
2008-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |